This ImmunoGuide anti-drug antibody(ies) (ADA) kit is a bridging type ELISA for the determination of free antibodies against the drug Vedolizumab in serum and plasma samples. During the first incubation period, ADA in serum or plasma samples are captured by the drug coated to the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled drug conjugate is added and then incubated. ADA, if present in the sample, will make a bridge, with its identical Fab arms, between the drug coated on the well and the other drug molecule labelled with peroxidase. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated by adding a stop solution. The positive reaction is expected to be related to the presence of ADA in the sample. Sample Types: serum, plasma. Range: Cut-off. Sensitivity: Cut-off. Time: 1.5 hours ? The drug Vedolizumab (trade name Entyvio?) is a humanised immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7, is indicated for the treatment of moderately to severely active ulcerative colitis [UC] or Crohn's disease [CD]. During treatment the presence of persistent anti-Vedolizumab antibody was observed to substantially reduce serum concentrations of Vedolizumab, either to undetectable or negligible levels. The Eagle Biosciences Antibody to Vedolizumab ELISA Assay kit has been designed for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug.
Size
1 x 96 well
Concentration
n/a
Applications
RUO
Other Names
anti-drug antibody kits, anti drug shikari shakari ,Entyvio, Antibodies, Antibody, ELISA Assay Kit EIA, Immunoassay, Vedolizumab, IG-BB116